⌕
DBV Technologies · DBVT · Nasdaq
Tenet 31 · Weak
Compare
$9.42−2.69%At closeTenet 31 · Weak
$9.42−0.26 (−2.69%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

DBV Technologies (DBVT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● The Motley FoolNov 18, 2026 · 14:45 ET
DBV Technologies: 3 Key Takeaways for Long-Term Investors

DBV submitted its BLA for VIASKIN Peanut in 4-to-7-year-olds. Existing cash of $165.7 million funds operations into third-quarter 2027.…

● MarketBeatNov 9, 2026 · 10:15 ET
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears

DBV Technologies NASDAQ: DBVT is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics license application, e…

● Seeking AlphaNov 6, 2026 · 23:24 ET
DBV Technologies: Down 55% Since April, Yet My $42 Fair Value Still Holds

DBV Technologies is rated Speculative Strong Buy with a $42 per ADS fair value, despite recent sector- and company-specific share price declines. My revised DCF incorporates higher discount rates, regulatory delay probab…

● GlobeNewsWireNov 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
DBV Technologies to Participate in Upcoming November Investor Conferences

Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stag…

● Seeking AlphaOct 28, 2026 · 23:00 ET
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript…

● MarketBeatOct 28, 2026 · 20:05 ET
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call

DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a …

● GlobeNewsWireOct 28, 2026 · 16:47 ETCOMPANY'S OWN WORDS
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update

Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged…

● GlobeNewsWireOct 27, 2026 · 16:30 ETCOMPANY'S OWN WORDS
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026

Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologi…

● Defense WorldOct 17, 2026 · 03:29 ET
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)

DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based o…

● Defense WorldOct 16, 2026 · 03:41 ET
DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low – What’s Next?

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.90 and last traded at $9.03, with a volume of 344,103 shares trad…

● Defense WorldOct 8, 2026 · 04:01 ET
DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low – Time to Sell?

Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $9.64 and last traded at $9.77, with a volume of 535276 shares changing hands. The stock ha…

● Defense WorldOct 3, 2026 · 05:01 ET
DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $11.76, but opened at $11.30. DBV Technologies shares last traded at $11.32, with…

● GlobeNewsWireSep 29, 2026 · 18:29 ETCOMPANY'S OWN WORDS
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results fro…

● Defense WorldSep 25, 2026 · 03:17 ET
DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis

DBV Technologies (NASDAQ: DBVT - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesse…

● GlobeNewsWireSep 3, 2026 · 16:32 ETCOMPANY'S OWN WORDS
DBV Technologies to Participate in Upcoming September Investor Conferences

Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-st…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just DBVT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.